Overview

• AstraZeneca became the second major drugmaker after Pfizer to publicly sign a pricing agreement at the White House, following an Oval Office unveiling with President Donald Trump.
• The company will offer up to 80% discounts on three branded respiratory medicines to cash‑paying patients through TrumpRx.gov, which is slated to launch in January 2026, with Medicaid receiving Most Favored Nation prices.
• In exchange, AstraZeneca said it will avoid 100% import tariffs on branded drugs for at least three years under the administration’s tariff framework announced in September.
• The deal accompanies a U.S. pivot that includes a $50 billion investment program and a rapidly negotiated $4.5 billion manufacturing facility in Virginia, with the company outlining plans to onshore production for the U.S. market.
• Analysts caution that deep cash discounts may offer limited relief for insured patients who rely on plan benefits, even as more pharma companies are expected to pursue similar agreements.